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1010Objective: The aim of this propensity-matched, multicenter study was to compare early clinical and echo-
cardiographic outcomes of patients undergoing transapical aortic valve implantation (TA-TAVI) versus
patients undergoing sutureless aortic valve replacement (SU-AVR) for severe symptomatic aortic valve
stenosis.
Methods:We reviewed 468 TA-TAVIs performed in 20 centers from April 2008 to May 2011, and 51 SU-
AVRs performed in 3 centers from March to September 2011. Based on a propensity score analysis, 2
groups with 38 matched pairs were created. Variables used in the propensity analysis were age, sex,
body surface area, New York Heart Association class, logistic EuroSCORE, peripheral vascular disease,
chronic obstructive pulmonary disease, aortic valve area, mitral regurgitation, and left ventricular ejection
fraction.
Results: Preoperative characteristics of the 2 groups were comparable. Hospital mortality was 5.3% and 0% in
the TA-TAVI and SU-AVR groups, respectively (P ¼ .49). We did not observe stroke or acute myocardial in-
farction in the 2 groups. Permanent pacemaker implantation was needed in 2 patients of each group (5.3%,
P ¼ 1.0). Dialysis was required in 2 patients (5.3%) in the SU-AVR group and in 1 patient (2.7%) in the
TA-TAVI group (P ¼ 1.0). Predischarge echocardiographic data showed that the incidence of paravalvular
leak (at least mild) was greater in the TA-TAVI group (44.7% vs 15.8%, P¼ .001), but there were no differences
in terms of mean transprosthetic gradient (10.3  5 mm Hg vs 11  3.7 mm Hg, P ¼ .59).
Conclusions: This preliminary experience showed that, in patients at high risk for conventional surgery, SU-
AVR is as safe and effective as TA-TAVI and that it is associated with a lower rate of postprocedural paravalvular
leak. (J Thorac Cardiovasc Surg 2012;144:1010-8)Surgical aortic valve replacement (SAVR) is the treatment
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The Journal of Thoracic and Cardiovascular Surstenosis (SSAVS) because it provides excellent early and
long-term clinical outcomes as well as good results in terms
of hemodynamics, valve durability, and freedom from
valve-related complications.1 Transcatheter aortic valve im-
plantation (TAVI) has shown excellent early and mid-term
clinical and hemodynamic results in inoperable or high-
risk patients with SSAVS.2,3 In particular, TAVI with
balloon-expandable bioprostheses has demonstrated better
results than medical therapy alone in inoperable patients4
as well as noninferiority to SAVR in high-risk elderly pa-
tients.5 TAVI using balloon-expandable valves can be ac-
complished with either an antegrade transapical access or
with a retrograde approach. The latter is usually performed
via a transfemoral access, but recently a transaortic ap-
proach has been described6,7; the transsubclavian access
is used less frequently. The transfemoral access is
generally considered the first choice because it is less
invasive and there is no need for general anesthesia and
tracheal intubation. However, transapical TAVI (TA-
TAVI) provides good results with a low incidence ofgery c November 2012
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
I-TA ¼ Italian Registry of Trans-Apical Aortic
Valve Implantation
NYHA ¼ New York Heart Association
SAVR ¼ surgical aortic valve replacement
SSAVS ¼ severe symptomatic aortic valve
stenosis
SU-AVR ¼ sutureless aortic valve replacement
TA-TAVI ¼ transapical transcatheter aortic valve
implantation
TAVI ¼ transcatheter aortic valve implantation
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Daccess-related complications, even in patients with severe
peripheral vascular disease.8 Recently, sutureless aortic
valve replacement (SU-AVR) has been proposed as addi-
tional therapeutic option for the treatment of high-risk pa-
tients with SSAVS because it provides good early clinical
and hemodynamic outcomes.9,10 Potential advantages of
SU-AVR over SAVR are related mainly to the removal of
the native aortic valve, to the shortening of aortic cross-
clamp time, and to the possibility of performing easier, min-
imally invasive access. Therefore, potential candidates for
SU-AVR are high-risk, operable patients who could benefit
from a shorter crossclamp time and/or from a minimally in-
vasive procedure. In other words, they belong to a ‘‘gray
zone’’ that includes patients who are at high risk for
SAVR but who are not really inoperable. Because TAVI
and SU-AVR are both aimed at the therapy of high-risk pa-
tients with SSAVS, the objective of this propensity-matched
multicenter study is to compare clinical and echocardio-
graphic outcomes at hospital discharge of patients undergo-
ing TA-TAVI versus patients undergoing SU-AVR.PATIENTS AND METHODS
This study was approved by the ethics committees, and patient informed
consent was collected.
Transapical Transcatheter Aortic Valve Implantation
We reviewed data from 566 patients enrolled in the Italian Registry of
Trans-Apical Aortic Valve Implantation (I-TA) from April 2008 through
May 2011. The I-TA is an independent, prospective, multicenter registry
that includes themajority of patients who have undergone TA-TAVI in Italy
with the Edwards Sapien/Sapien XT pericardial bioprosthesis (Edwards
Lifesciences, Irvine, Calif) since this procedure became available in April
2008. Details about the I-TA, participating centers and investigators, indi-
cations for TA-TAVI, device characteristics, sizing and surgical technique,
postoperative medications, and data collection and analysis have been de-
scribed previously.11 To avoid potential selection bias, we excluded from
the current analysis 98 inoperable patients who underwent TA-TAVI for
porcelain aorta. Consequently, we took into consideration the data from
468 patients in the I-TA who represent the unmatched TA-TAVI cohort
of this study.The Journal of Thoracic and CarSutureless Valve
We collected and analyzed data prospectively of 51 patients who under-
went SU-AVR with the Perceval S bioprosthesis (Sorin Biomedica Cardio,
Saluggia, Italy) at 3 Italian centers from March to September 2011. These
patients represent the entire experience of the 3 participating institutions.
Sutureless valve data were collected using the same data set of the I-TA
to obtain homogeneous, comparable, and, most important, reliable data.
The Perceval S is made of 3 bovine pericardium leaflets mounted on
a self-expandable metallic stent. SU-AVR was performed with either full
sternotomy, mini sternotomy or mini thoracotomy, according to the type
of intervention, the associated procedures, and, ultimately, the surgeon’s
preferences. In particular, full sternotomy, mini sternotomy, and mini right
thoracotomy in the second intercostal space12 were performed in 36
(70.6%), 4 (7.8%), and 11 (21.6%) patients, respectively.All SU-AVRpro-
cedures were performed under moderately hypothermic (32C) cardiopul-
monary bypass with aortic crossclamping and cardioplegic arrest of the
heart. A transverse aortotomy was performed around 3 to 3.5 cm above
the aortic annulus, the native valve was removed, and annular decalcifica-
tion was performed. Annular decalcification is not as extensive as for con-
ventional surgery, but it is aimed at removing bulky calcifications to obtain
a homogeneous, round-shaped annulus for sutureless valve implantation.
After decalcification, the aortic annulus was sized and the correct prosthesis
was selected. Prosthesis size ‘‘small’’ was selected, with an annulus diam-
eter between 19 mm and 21 mm. Size ‘‘medium’’ was selected, with an an-
nulus diameter between 21 mm and 23 mm. During the study period, size
‘‘large’’ was still not available. Three 4-0 prolene guiding sutures are passed
through the aortic annulus at the nadir of each sinus. The delivery system
was guided in its correct position using these sutures and the valve was
deployed.After deployment, the delivery system and sutureswere removed,
and aballoonwas inserted in thevalveandexpanded for 30 seconds at a pres-
sure of 3 atm. The ascending aorta was then closed according to the usual
technique (Figure 1). Further details about Perceval S implantation tech-
nique have been described previously.9,13 Indications for SU-AVR were
as follows: SSAVS defined by a valve area less than 0.8 cm2 andmean trans-
aortic gradient more than 40 mmHg, and a high surgical risk profile for ad-
vanced age (>75 years), comorbidities, and patient frailty. Because there are
no guidelines and/or recommendations for SU-AVR and experience is still
limited, we did not use strict EuroSCORE or Society of Thoracic Surgeons
score cutoff values as inclusion criteria. The decision to perform SU-AVR
instead of SAVR or TAVI was made by the cardiac surgeon and was based
mainly on a careful evaluation of the patient’s preoperative characteristics
and on clinical observation. Contraindications for the use of the Perceval
S valve were previous implantation of a valve prosthesis or annuloplasty
ring not being replaced by the sutureless bioprosthesis, double- or
multiple-valve surgery, aneurysmal dilatation (45 mm) or dissection of
the ascending aorta, active endocarditis, bicuspid aortic valve, and recent
myocardial infarction (<90 days). A complete preoperative echocardio-
graphic examination was performed in all patients to assess diameters of
the aortic annulus, root, and sinotubular junction, and to measure the height
of the aortic root (from the aortic annulus to the sinotubular junction). Pa-
tients were deemed suitable for a Perceval S implantation if the sinotubular
junction diameter/annulus diameter ratio was 1.3. Postoperatively, all
patients with SU-AVR received aspirin 100 mg daily, whereas patients
with chronic atrial fibrillation received oral anticoagulation therapy.
Patients in both groups underwent clinical and echocardiographic
assessment at the study site before the operation and at hospital discharge.
Echocardiographic measurements were acquired according to current rec-
ommendations.14 Transvalvular pressure gradients were derived by using
the modified Bernoulli equation. Prosthetic aortic regurgitation was classi-
fied as none or trace, mild (1þ/3þ), moderate (2þ/3þ), or severe (3þ/3þ) ac-
cording to recent recommendations.15 Preoperative risk factors were
defined according to the EuroSCORE I classification,16 and postoperative
outcomes were defined according to the Valve Academic Research
Consortium definitions.17diovascular Surgery c Volume 144, Number 5 1011
FIGURE 1. A, The Perceval S sutureless aortic bioprosthesis. The pericardial leaflets and the Nitinol frame are clearly visible. B, The bioprosthesis is
collapsed on the holder. Three sutures are passed through a slot corresponding to the middle of each prosthetic leaflet and through the nadir of each native
aortic sinus to allow for correct positioning of the valve. C, The valve is deployed in its correct position. D, Intraoperative transesophageal echocardiography
showing the Perceval S (arrows) positioned correctly in the aortic annulus and in the aortic root.
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Continuous variables with a normal distribution are expressed as
means 1 standard deviation; those with a nonnormal distribution (as-
sessed by the Shapiro-Wilk normality test) are presented as median and
interquartile range (25% to 75%). Categorical data are summarized by
reporting absolute frequency distribution and percentage. Categorical var-
iables were compared using the c2-test or Fisher’s exact test as appropri-
ate. Student t test (for unpaired data) or the Mann-Whitney test were used
to compare continuous variables, as appropriate. Propensity score match-
ing analysis was used to adjust for baseline characteristic differences be-
tween the 2 groups (1-to-1 matching based on propensity scores). The
propensity score was estimated by a logistic regression model for each
patient. Matching using calipers of width of 0.2 of the standard deviation
of the logit of the propensity score was performed according to the sug-
gestions of Austin.18 Variables used in the propensity analysis were age,
sex, body surface area, New York Heart Association (NYHA) class, logis-
tic EuroSCORE, peripheral vascular disease, chronic obstructive pulmo-
nary disease, aortic valve area, mitral regurgitation, and left ventricular
ejection fraction. The propensity c statistic was 0.96. Comparisons be-
tween group outcomes were carried out by taking into consideration
the matched nature of the propensity score-matched sample. In particular,
the paired t-test or Wilcoxon’s signed-rank test were used for continuous
variables and the McNemar test was used for binary (dichotomous) vari-
ables. Statistical findings were considered significant if the critical level
was less than 5% (P< .05). Statistical analysis was performed using1012 The Journal of Thoracic and Cardiovascular SurSTATA software (release 10.0 for Windows; Stata Corporation LP, Col-
lege Station, Tex).RESULTS
Preoperative clinical and echocardiographic variables of
the unmatched TA-TAVI (468 patients) and SU-AVR (51
patients) patient populations are listed in Table 1. In the un-
matched cohort, TA-TAVI patients were more likely to have
peripheral vascular disease and chronic obstructive pulmo-
nary disease than SU-AVR patients. Furthermore, TA-TAVI
patients had a significantly higher logistic EuroSCORE
value, higher NYHA class, and lower left ventricular ejec-
tion fraction. After propensity analysis and matching, 2
groups of 38 patients each were created: the TA-TAVI group
and the SU-AVR group. Preoperative clinical characteris-
tics of the matched groups are listed in Table 2. The 2
groups were comparable in terms of preoperative character-
istics. In particular, in TA-TAVI– and in SU-AVR–matched
patients, the logistic EuroSCORE (14.8  7.5% vs 13.7 
7.2%, P ¼ .47) and age (80.9  6.9 years vs 80.9  3.9
years, P ¼ .92) were similar, as well as NYHA functionalgery c November 2012
TABLE 1. Preoperative data of the unmatched populations
Variable TA-TAVI (n ¼ 468) SU-AVR (n ¼ 51) P Value
Age, y (IR) 82 (78-86) 80 (76-83) .007
Male sex, n (%) 190 (40) 6 (12) <.001
Hypertension, n (%) 374 (79.9) 37 (72.6) .21
Diabetes, n (%) 126 (26.9) 13 (25.5) .82
NYHA class 3, n (%) 381 (81.4) 30 (58.9) <.001
Peripheral vascular disease, n (%) 180 (38.4) 5 (9.8) <.001
COPD, n (%) 150 (32.1) 7 (13.7) .007
Neurologic dysfunction, n (%) 31 (6.6) 1 (2) .35
Dialysis, n (%) 6 (1.3) 1 (2) .51
Logistic EuroSCORE,% 26  14.4 14.2  8.1 <.001
Coronary artery disease, n (%) 115 (24.6) 13 (25.5) .88
Previous cardiac surgery, n (%) 73 (15.6) 4 (7.8) .21
Atrial fibrillation, n (%) 98 (21.3) 6 (11.8) .14
LVEF,% (IR) 55 (45-60) 60 (55-66) .003
Mean transaortic gradient, mm Hg (IR) 51 (41-60) 47 (42-54) .17
Aortic valve area index, cm2/m2 (IR) 0.50 (0.40-0.69) 0.47 (0.40-0.59) .03
Pulmonary artery pressure, mm Hg (IR) 44 (35-55) 40 (34.5-45) .01
TA-TAVI, Transapical aortic valve implantation; SU-AVR, sutureless aortic valve replacement; IR, interquartile range; NYHA, New York Heart Association; COPD, chronic
obstructive pulmonary disease; LVEF, left ventricular ejection fraction.
D’Onofrio et al Acquired Cardiovascular Disease
A
C
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dence of chronic obstructive pulmonary disease. In the
TA-TAVI group, prosthesis sizes of 23 mm and 26 mm
were used in 16 patients (42.1%) and 22 patients
(57.9%), respectively; in the SU-AVR group, size small
and size medium were used in 17 patients (44.7%) and 21
patients (52.3%), respectively. In the SU-AVR group, 12
patients (31.6%) underwent associated coronary artery by-
pass grafting (CABG) whereas in the TA-TAVI group, 10
patients (26.3%) underwent coronary stenting pre-TAVI.
Previous cardiac operations were performed in 3 patients
(7.9%) and in 5 patients (13.2%) in the SU-AVR groupTABLE 2. Preoperative characteristics of the two matched groups
Variable TA-TAVI (n ¼ 3
Age, y 80.9  6.9
Male sex, n (%) 8 (21.1)
Hypertension, n (%) 31 (81)
Diabetes, n (%) 10 (26)
NYHA class 3, n (%) 28 (73.7)
Peripheral vascular disease, n(%) 7 (18.4)
COPD, n (%) 8 (21.1)
Neurologic dysfunction, n (%) 2 (5)
Dialysis, n (%) 0
Logistic EuroSCORE,% 14.8  7.5
Coronary artery disease, n (%) 17 (45)
Previous cardiac surgery, n (%) 5 (13.2)
Atrial fibrillation, n (%) 5 (13.1)
LVEF,% (IR) 60 (55-65)
Mean transaortic gradient, mm Hg (IR) 51.3  5.8
Aortic valve area index, cm2/m2 (IR) 0.50 (0.40-0.63
Pulmonary artery pressure, mm Hg 40.2  14.7
TA-TAVI, Transapical aortic valve implantation; SU-AVR, sutureless aortic valve replace
disease; LVEF, left ventricular ejection fraction; IR, interquartile range.
The Journal of Thoracic and Car(2 previous CABG and 1 SAVR) and in the TA-TAVI group
(previous CABG in all 5 patients), respectively (P¼ .71). In
SU-AVR group, mean cardiopulmonary bypass time and
aortic crossclamp time were 69  26 minutes and 44 
17 minutes, respectively, for isolated procedures, and 74
 26 minutes and 50 20 minutes, respectively, for the en-
tire cohort. Postoperative outcomes are shown in Table 3.
Hospital mortality occurred in 2 patients in the TA-TAVI
group (5.3%). Causes of hospital mortality were severe
bleeding secondary to rupture of the aortic annulus and car-
diogenic shock with multiorgan failure in 1 patient each. No
hospital mortality occurred in the SU-AVR group (P¼ .49).8) SU-AVR (n ¼ 38) P Value
80.9  3.9 .92
6 (15.8) .77
28 (74) .58
8 (21) .79
25 (65.8) .60
5 (13.2) .68
5 (13.2) .54
1 (3) 1.00
1 (3) 1.00
13.7  7.2 .47
13 (34) .45
3 (7.9) .71
6 (15.8) 1.00
60 (55-65) .99
48  9.1 .31
) 0.45 (0.40-0.60) .62
39.5  9.6 .87
ment; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary
diovascular Surgery c Volume 144, Number 5 1013
TABLE 3. Postoperative outcomes after TA-TAVI and SU-AVR
Variable TA-TAVI (n ¼ 38) SU-AVR (n ¼ 38) P Value
Hospital mortality, n (%) 2 (5.3) 0 (0) .49
ARF requiring CVVH, n (%) 1 (2.6) 2 (5.3) 1.00
AMI, n (%) 0 (0) 0 (0) 1.00
Stroke, n (%) 0 (0) 0 (0) 1.00
Bleeding (life-threatening/disabling, major), n (%) 2 (5.3) 1 (2.6) 1.00
PPM implantation, n (%) 2 (5.3) 2 (5.3) 1.00
Mean transaortic gradient, mm Hg 10.25  5.03 10.95  3.72 .59
AR at discharge (at least mild), n (%) 17 (44.7) 6 (15.8) .001
LVEF at discharge,% (IR) 60 (55-60) 60 (54-65) .75
New-onset atrial fibrillation, n (%) 7 (18.4) 16 (42.1) .04
Orotracheal intubation time, hours (IR) 4 (0-5) 5.5 (4-8) .21
TA-TAVI, Transapical aortic valve implantation; SU-AVR, sutureless aortic valve replacement; ARF, acute renal failure;CVVH, continuous venovenous hemofiltration; AMI, acute
myocardial infarction; PPM, permanent pacemaker; AR, aortic regurgitation; LVEF, left ventricular ejection fraction; IR, interquartile range.
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tients (5.3%) from each group (P ¼ 1.00), whereas tempo-
rary renal replacement therapy with continuous venovenous
hemofiltration was needed in 2 patients (5.3%) in SU-AVR
group and in 0 patients in the TA-TAVI group (P ¼ .49).
Postoperative atrial fibrillation occurred in 16 patients
(42.1%) and in 7 patients (18.4%) in the SU-AVR and
TA-TAVI groups, respectively (P ¼ .04). We observed 1
life-threatening/disabling bleeding event (fatal bleeding)
that caused patient death and 1 major bleeding in the TA-
TAVI group (5.3%), and 1 life-threatening/disabling bleed-
ing event in the SU-AVR group (2.6%; P ¼ 1.00). Device
success was 97.4% (37 of 38 patients; 1 patient needed
a 2nd prosthesis for malposition) in the TA-TAVI group
and 100% in the SU-AVR group (P ¼ 1.00). Predischarge
echocardiographic examination showed no differences in
mean transprosthetic gradients (TA-TAVI: 10.25  5.03
mm Hg vs SU-AVR: 10.95  3.72 mm Hg, P ¼ .59), effec-
tive orifice area index (TA-TAVI: 1.1 0.21 cm2/m2 vs SU-
AVR: 1.01  0.22 cm2/m2, P ¼ .64), and left ventricular
ejection fraction between groups. On the other hand, we ob-
served a significantly higher incidence of paravalvular leak
(at least mild, 1þ/3þ) in TA-TAVI patients (17 patients,
44.7% vs 6 patients, 15.8%; P ¼ .001). In particular, of
the 17 TA-TAVI patients with paravalvular regurgitation,
we observed a mild leak (1þ/3þ) in 14 patients and a moder-
ate leak (2þ/3þ) in 3 patients. Conversely, in the SU-AVR
group, the observed paravalvular leak was always mild.
We did not observe any stroke or acute myocardial infarc-
tion in the 2 groups.
DISCUSSION
During the past few years, many authors have investi-
gated clinical and hemodynamic outcomes of TAVI, and
yet few data exist regarding SU-AVR. To the best of our
knowledge, this is the first study comparing TAVI and
SU-AVR. In this study we examined 2 high-risk (age,>80
years; logistic EuroSCORE, 15%), propensity-matched1014 The Journal of Thoracic and Cardiovascular Surcohorts undergoing TA-TAVI or SU-AVR for SSAVS. We
did not observe significant differences in hospital mortality,
severe postoperative complications, and transprosthetic
gradients between groups. However, we found a higher in-
cidence of paravalvular leak in the TA-TAVI group and an
increased rate of new-onset postoperative atrial fibrillation
in the SU-AVR group. For every surgical technique, a cor-
rect selection of candidates is mandatory to achieve optimal
results and, consequently, to improve patient outcome.With
the introduction of sutureless aortic valve bioprostheses into
clinical practice the portfolio of aortic valve substitutes can
be considered complete. Patients with SSAVS can be sched-
uled for SAVR, TAVI, or SU-AVR according to their preop-
erative clinical features, anatomic characteristics, and risk
profile. Although there is no doubt that nonelderly patients
with a low surgical risk should undergo SAVR, and that very
high-risk or inoperable patients could benefit from TAVI,
the optimal treatment for high-risk operable patients is still
controversial. In this analysis, among all TA-TAVI patients
enrolled in the I-TA, propensity score and matching se-
lected those with the lowest logistic EuroSCORE values.
These patients have a high but not a very-high risk profile
and belong to a ‘‘gray zone’’ where there is an overlap of
indications for each treatment strategy; SAVR, TAVI, and
SU-AVR are all potential therapeutic options. The
decision-making process should be based on the character-
istics of each substitute and on their advantages and disad-
vantages. SAVR remains the first choice for the treatment of
SSAVS because it is well reproducible and offers optimal
technical, clinical, and hemodynamic outcomes in the great
majority of patients. The advantages of TAVI over SAVR
are related mainly to its less invasiveness as a result of the
absence of extracorporeal circulation and aortic cross-
clamping, the short duration of the procedure, and reduced
surgical trauma. These features make TAVI a good option in
inoperable4 or in very high-risk patients.5 On the other
hand, SU-AVR requires extracorporeal circulation and aor-
tic crossclamping, but their duration should, theoretically,gery c November 2012
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crossclamping duration play a significant role in patient out-
comes because they have been demonstrated to be indepen-
dent predictors of 30-day postoperative mortality after adult
cardiac surgery.19 Although, in our study, crossclamping
and extracorporeal circulation were similar to those
reported in the literature for conventional SAVR,20 it has
been shown that, in isolated SU-AVR, mean aortic clamp
time can be as low as 18 minutes,9 which is most likely re-
lated to the learning curve and to surgical experience. Fur-
thermore, our series included patients whowere operated on
through minimally invasive approaches (mini sternotomy
and mini right thoracotomy) that may require longer cross-
clamp times, especially when new technologies are used.
High-risk patients undergoing associated procedures are
those who probably benefit most from the reduction of
crossclamp and cardiopulmonary bypass time. In our
matched cohort, one third of SU-AVR patients underwent
associated CABG, and 20% of TA-TAVI patients under-
went coronary stenting prior to the aortic valve procedure,
without any postoperative acute myocardial infarction in
the 2 groups. Thus, we can speculate that among high-risk
patients with combined coronary artery disease and SSAVS,
thosewith percutaneous coronary intervention–eligible cor-
onary artery lesions can be selected for staged PCI and
TAVI whereas those deemed untreatable with PCI can be
scheduled for SU-AVR and associated CABG. Larger pro-
spective studies are needed to confirm this inference.
Although TAVI represents a well-established tech-
nique for the treatment of SSAVS, it is associated with
a noticeable rate of paravalvular leak. In our TA-TAVI
matched population, a significant paravalvular leak (at
least mild, 1þ/3þ) was found in 17 patients (44.7%);
in particular, a mild leak and a moderate leak were
found in 14 and in 3 patients, respectively. A signifi-
cantly lower incidence of paravalvular aortic regurgita-
tion was observed in the SU-AVR population (6
patients with a mild leak, 15.8%, P ¼ .001). A recently
published update of the Placement of Aortic Transcath-
eter Valve (PARTNER) trial shows that the incidence of
paravalvular leak is significantly higher after TAVI than
after SAVR at both 1 year and 2 years.21 Paravalvular
leak has a major impact on patient outcome; in fact, in
the PARTNER trial, the presence of paravalvular aortic
regurgitation after TAVI was associated with an in-
creased rate of late mortality, the effect of aortic regur-
gitation on mortality was proportional to the severity of
regurgitation, and even mild aortic regurgitation was as-
sociated with an increased rate of late deaths.21 Further-
more, postprocedural paravalvular leak was identified as
an independent predictor of late mortality after TAVI
(hazard ratio, 3.79).22,23 In this scenario, the finding of
a low paravalvular leak rate after SU-AVR is of great
importance during the decision-making process for theThe Journal of Thoracic and Carchoice of the valve substitute. The incidence of mild
(1þ/3þ) paravalvular leak in the sutureless group found
in this study (15%) was similar to that reported in an-
other series9 and should be considered acceptable be-
cause this was an initial experience with all the
learning curve-related issues. In fact, there are still
many things to learn in terms of patient selection, pros-
thesis sizing, positioning, and annular decalcification.
We are not surprised by the higher incidence of postop-
erative atrial fibrillation in the SU-AVR group because
this procedure is a true open-heart surgery. The occur-
rence of atrial fibrillation after cardiac surgery is associ-
ated with important complications, such as cognitive
changes, renal dysfunction, and infection,24 that in
a high-risk population may have a significant impact
on patient outcomes.
This study has several limitations. The analysis was per-
formed on a small number of patients and only on hospital
outcomes. The small number of matched pairs derives
from the relatively small general SU-AVR population
(51 patients) and from the covariates selected for match-
ing, which led to the creation of 2 perfectly matched
groups (c statistic, 0.96) including 38 patients each. TA-
TAVI surgery was started before SU-AVR and, conse-
quently, for some patient the 2 options were not available.
However, definitive patient selection was always made af-
ter multidisciplinary discussion. Echocardiographic ex-
aminations were performed by different physicians using
different machines, and we did not have a central echo
core lab. Adverse events were assigned by each center
and were not reviewed by an ad hoc committee. To give
a correct interpretation of these data we must highlight
that (1) we considered only TA-TAVI and (2) both Sapien
and Sapien XT were included. The decision to include
transapical patients only was based mainly on the impos-
sibility of collecting data from all Sapien–Italian transfe-
moral patients, because a specific registry of this kind
does not exist. Because most TAVI programs are based
on a transfemoral-first policy, TA-TAVI patients generally
have a higher risk profile than transfemoral patients,25 al-
though no significant differences in outcomes have been
observed.26 Sapien and Sapien XT have a different inci-
dence of paravalvular leak because of their slightly differ-
ent design. Furthermore, the Sapien valve was used during
our early experience when the learning curve, especially
regarding sizing and positioning, was new. This was a pre-
liminary experience; further larger and possibly prospec-
tive, randomized studies that include all TAVI
approaches are needed to confirm these results and to eval-
uate medium- and long-term outcomes in terms of sur-
vival, device durability, and freedom from valve-related
adverse events.
In conclusion, our data suggest that SU-AVR is as safe
and effective as TA-TAVI in high-risk patients with SSAVS.diovascular Surgery c Volume 144, Number 5 1015
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DSU-AVR is associated with a lower incidence of paravalvu-
lar leak but with a higher incidence of postoperative atrial
fibrillation. A center that has the ability to perform SAVR,
TAVI (with all its approaches), and SU-AVR is able to offer
the full spectrum of available therapeutic options for
SSAVS and, consequently, can choose the best treatment
for each patient, according to his or her specific clinical
and anatomic features.
The authors are sincerely grateful toMarco De Franceschi, BSc,
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Dr Thierry P. Carrel (Berne, Switzerland). Thank you very
much for the privilege of discussing this paper. The portfolio of
aortic valve replacement has recently been extended by several su-
tureless aortic valve prostheses that have been introduced on the
European market in recent years, but there is no clear-cut indica-
tion for these new types of valves so far. They are all restricted
to the treatment of a stenotic aortic valve, and the main advantage
claimed by the manufacturers is the reduction of the aortic cross-
clamp time. Some recent studies on very limited patient popula-
tions seem to confirm these findings so far.
In isolated aortic valve replacement, the crossclamp time is the
major determinant of cardiopulmonary bypass duration, but less
evidence exists of the role of the crossclamp time in affecting
the outcome neither in the general cardiac population nor in the
specific population treated for isolated aortic valve stenosis. No
study so far has addressed the selection of patients at particular
benefit for a significant reduction in crossclamp time for aortic
valve stenosis.
So the current study, although it addresses only certain interest-
ing aspects of aortic valve replacement, is a timely, nice studygery c November 2012
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procedure is the optimal one to treat aortic valve stenosis on an in-
dividual case-by-case appreciation. And the most interesting mes-
sage is that the incidence and severity of paravalvular leakage was
higher in the TAVI group than in the surgical group, although 15%
of paravalvular leakage is still not acceptable for a surgical
procedure!
So I have three questions for the authors. Could you give a short
comment on the learning curve to feel comfortable when using
a sutureless valve, and which surgical access do you consider to
be the best one for a sutureless valve implantation? Frankly speak-
ing, I found 44 minutes still a long crossclamp time for isolated su-
tureless valve implantation, and I ask this question because we
have found sutureless valve implantation through a less-invasive
approach to be somewhat cumbersome as long as the introducing
devices for these valves are not flexible enough to permit easy de-
ployment under perfect visualization.
Second question: A large majority of TAVI procedures are per-
formed through a transfemoral approach worldwide. Why did you
select only the transapical approach as a comparison group when
the sutureless valves may well address also those patients sched-
uled for a transfemoral approach?
And finally, I would like to question the size of the aortic annu-
lus. Because TAVI was available for sizes 23 and 26, but sutureless
valves only for sizes 21 and 23, do you think that the absence of
difference in the pressure gradients seen in the postoperative
echo between these 2 valves is a result of the fact that large sizes
were implanted only in TAVI and smaller sizes in sutureless
valves? I would expect sutureless performing much better than
TAVI, because the valve can be excised during a sutureless valve
procedure.
Thank you very much again.
Dr D’Onofrio. Dr Carrel, thank you for your questions. The
learning curve of sutureless aortic valve implantation is less de-
manding than the learning curve for TAVI, especially for cardiac
surgeons, who are more used to a surgical approach than to a cath-
eter-based approach.
Crossclamp time in this series for isolated valve replacement
was 44 minutes, but in the literature it has been shown that the
crossclamp time can be as low as 18 minutes. I believe that this dif-
ference is mainly a result of the learning curve and the fact that
these were the very first cases that we have done in Italy. Regard-
less, we observe that, as experience increases, the crossclamp
times reduce progressively. So I am pretty sure that, in future stud-
ies, we will show shorter crossclamp times.
The great majority of centers that participate to the Italian
Transapical registry, called ITA, are based on a transfemoral-first
approach. Our registry includes only transapical procedures, and
for this study we didn’t have the possibility to retrieve transfemoral
data as well. However, because transfemoral procedures are per-
formed mainly by interventional cardiologists, in this study we ob-
served cardiac surgeons performing both transcatheter and
surgical procedures, and this is quite interesting.
There were no differences in terms of gradients between trans-
apical and sutureless valves. It is a very small series, so I don’t
think we can draw any final conclusion from this study. Actually,
I don’t think that label size has a big importance regarding trans-
valvular gradients.The Journal of Thoracic and CarI hope I answered all your questions.
Dr Joseph F. Sabik (Cleveland, Ohio). I have a question about
the technical aspects of deploying the sutureless valves. How ag-
gressive do you debride the calcium in the aortic annulus? Do
you want some calcium left behind to hold the valve in place—
let’s just say like a transcatheter valve—or do you want to debride
it aggressively like we would do in an open procedure?
DrD’Onofrio.We take the calciumaway fromthe annulus, but it
is not important to take away everything as for conventional valves.
We just want to have a homogenous, round-shaped annulus even
with some calcium, so that the valve can be implanted smoothly.
Dr Sabik. Does debridement influence whether you have any
leakage around the valve?
Dr D’Onofrio. Sorry?
Dr Sabik. How aggressively you debride, does that influence
the leakage around the valve, if there is any, any paravalvular aortic
insufficiency?
Dr D’Onofrio.Yes, we observed a small incidence of paravalv-
ular leak in sutureless valves. The most important thing is to have
a round-shaped homogeneous debridement without bulky pieces
of calcium in the annulus before sutureless valve implantation.
We did not observe a relationship between the extension of annular
decalcification and paravalvular leak.
Dr Khaled D. Algarni (Toronto, Ontario, Canada). You have
done a very good job trying to match these 2 groups; however,
frailty is an important confounder that you perhaps haven’t ac-
counted for. Do you think that in the TAVI group there were
more patients who were frail than in the sutureless valve group?
And that might explain the higher mortality in the TAVI group?
Dr D’Onofrio. Of course, frailty is important, but we didn’t
collect specific data about this aspect, so we were not able to in-
clude any frailty index as a variable into the statistical analysis.
The logistic EuroSCORE of the matched TAVI population was
lower than the logistic EuroSCORE of the entire TAVI cohort.
This is because propensity matching selected patients with a low
logistic EuroSCORE. And the indication of these patients for
TAVI was based mainly on frailty, rather than on EuroSCORE,
but unfortunately we don’t have a numeric value for that.
Dr Mustafa Cikirikcioglu (Geneva, Switzerland). First of all,
I congratulate the authors for a timely report on sutureless aortic
valves. My question is concerning the paravalvular leak rate.
You announced 15% of paravalvular leak for the Perceval
group. Do you think this is an acceptable percentage for a surgi-
cal aortic valve replacement group? And my second question:
Why did you not choose a third group of patients that would
include only surgically and standard aortic valve replacement?
Thank you.
Dr D’Onofrio. I want to answer your second question first. We
are now designing a new study considering all 3 groups—trans-
catheter, sutureless, and surgical aortic valve. I hope it will be
done in the very near future.
Dr Cikirikcioglu. And, in your opinion, is it acceptable?
Dr D’Onofrio.We have to consider that this is just a very pre-
liminary and a very initial experience, so there is a learning curve.
The leaks were always mild, and I think that in the future the inci-
dence of paravalvular leak will go down for sure. It is like trans-
catheter valves; we are now learning how to make sizing, how to
make deployment. We are learning a lot of things, and I thinkdiovascular Surgery c Volume 144, Number 5 1017
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learning curve, I believe that results will improve.
Dr Keith B. Allen (Kansas City, Mo). I want to follow up on
that last question. We know from recent PARTNER data that
even mild paravalvular leak has a negative impact on mortality.
You may not have known that when you were doing this study
but, moving forward, is that knowledge going to change how
you will use the sutureless valve? Because you have the patient
open and on bypass, and putting in some type of a sewn-in valve
may only add 10 or 15 minutes to the operation without the com-
plication of paravalvular leaks?
Dr D’Onofrio. Yes, I totally agree with you. Paravalvular leak
is a very important determinant of early and late results in aortic
valve patients, and I think that with sutureless valves we just
have to identify who are the right patients who need this procedure.
And for this reason, I think we have to find a compromise and to
accept a low rate of paravalvular leak. However, as I said before,1018 The Journal of Thoracic and Cardiovascular Surwith the learning curve and with experience I think that our results
will improve for sure.
Dr Behzad Soleimani (Hershey, Pa). Thank you for your clear
presentation. I have a question again on the paravalvular leak in
the sutureless group. How many of the paravalvular leaks were
detected at the end of the procedure with on-table transesopha-
geal echocardiogram (TEE)? And second, if you had more than
mild AI, what would have been your strategy in the operating
room?
Dr D’Onofrio. Four of these minor leaks were found at predis-
charge examination, and only 2 were found on the intraoperative
TEE. We decided not to touch these minor leaks, because the pro-
cedure was really complex and it would have been worse to clamp
the aorta again to fix just a minor leak. In case a moderate leak is
found, the behavior is similar to conventional aortic valve replace-
ment. If we find a moderate leak, we go on pump again, we clamp
the aorta, and we fix it.gery c November 2012
